{
    "clinical_study": {
        "@rank": "73696", 
        "arm_group": {
            "arm_group_label": "Type 1 Diabetes", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The investigators are doing this research study to compare the pharmacokinetics (rate of\n      absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine\n      (Apidra) within individual subjects."
        }, 
        "brief_title": "Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 1"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 12 years or older with clinical type 1 diabetes for at least five years\n\n          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting\n             insulins including insulin aspart (NovoLog), insulin lispro (Humalog), and insulin\n             glulisine (Apidra).\n\n          -  Ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 9\n             units of rapid acting insulin\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent\n\n          -  Unable to comply with study procedures\n\n          -  Inadequate venous access as determined by study nurse or physician at time of\n             screening.\n\n          -  Pregnancy\n\n          -  History of gastric banding, gastric bypass, or other gastrointestinal condition that\n             may prevent a subject from consuming a normal sized meal\n\n          -  Hemoglobin <13.5 for men, < 12 for women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684943", 
            "org_study_id": "2010P001005"
        }, 
        "intervention": {
            "arm_group_label": "Type 1 Diabetes", 
            "intervention_name": "insulin analog administration", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "March 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Aggregate mean difference in tmax between the analog with greatest and the analog with the least value of tmax for individual subjects.", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684943"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven J. Russell, MD, PhD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects with a difference in tmax between analogs will be catagorized as follows: using insulin with best PK for them, using insulin with worst PK for them, or using insulin with intermediate PK for them. Whether there is a difference between the median A1c between these three groups will be tested with the Kruskal-Wallis one-way analysis of variance test. In addition whether there is a difference in the fraction of subjects in these groups meeting their A1c goal of less than or equal to 7% (i.e. whether the analog choice and meeting the A1c target are independent) will be determined with the chi-square test.", 
                "measure": "Correlation between HbA1c at study entry and use of insulin analog with most favorable PK as an outpatient for subjects with a difference in tmax between analogs.", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Fraction of subjects with difference in tmax between the analog with greatest and the analog with the least value of tmax that is > 25%", 
                "safety_issue": "No"
            }, 
            {
                "description": "Subjects with a difference in tmax between analogs will be catagorized as follows: using insulin with tmax less than or equal to 60 minutes or using insulin with tmax > 60 minutes. Whether there is a difference between the median A1c between these two groups will be tested with the heteroskedastic Student's t test.", 
                "measure": "Correlation between HbA1c at study entry and use of insulin analog with tmax < 60 minutes as an outpatient vs. use of an insulin analog with tmax > 60 minutes as an outpatient.", 
                "safety_issue": "No"
            }, 
            {
                "description": "Subjects with a difference in tmax between analogs will be catagorized as follows: using insulin with best PK for them, using insulin with worst PK for them, or using insulin with intermediate PK for them. Whether there is a difference between the number of hypoglycemic episodes per month between these three groups will be tested with the Kruskal-Wallis one-way analysis of variance test. In addition whether there is a difference in the fraction of subjects in these groups with less than or equal to two episodes of hypoglycemia a week (i.e. whether the analog choice and the frequency of hypoglycemia are independent) will be determined with the chi-square test.", 
                "measure": "Correlation between number of monthly self-reported or meter recorded incidents of hypoglycemia at study entry and use of insulin analog with best PK kinetics.", 
                "safety_issue": "No"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}